Skip to main content
. 2015 Dec 17;10(4):402–409. doi: 10.1093/ecco-jcc/jjv226

Figure 5.

Figure 5.

Patients remaining on vedolizumab. Kaplan–Meier analysis illustrating the rate of vedolizumab continuance for both ulcerative colitis and Crohn’s disease patients carried out to week 52 as available. (A) Prospective study cohort (n = 51; UC = 21, CD = 30). (B) All patients starting vedolizumab (n = 102; UC = 45, CD = 57). The numbers of subjects at risk are listed by time point in weeks.